In August 2016, Astrazeneca had announced the termination of distribution arrangement by AstraZeneca UK for Meronem in India, pursuant to a global agreement by AstraZeneca PLC to sell the development and commercialisation rights to Pfizer Inc., of its late stage small molecule antibiotics business.

Further in December 2016, the validity period of the distribution agreement was extended till 31 July 2017, due to delay in the divestment of AstraZeneca's global rights to Meronem.